Patients with nonresectable liver metastases from colorectal cancer have few therapeutic options and a dismal prognosis. Although liver transplantation for this indication has historically a poor reputation, recent advances in the field of chemotherapy and immunosuppression have paved the way to revisit the concept. New data have shown promising results that need to be validated in several ongoing clinical trials. Since liver grafts represent a scarce resource, several new tools are being explored to expand the donor pool for this indication. The purpose of this review is to present all current available data and perspectives about liver transplantation for nonresectable liver metastases from colorectal cancer.
24 July 2025 in American Journal of Gastroenterology
INTRODUCTION: Primary sclerosing cholangitis (PSC) may recur after liver transplantation (LT). We aimed to evaluate the incidence of recurrent PSC (rPSC), its characteristics, and risk factors, in a large cohort with long-term follow-up. METHODS: We conducted a nationwide multicenter retrospective study in France, including all adult patients transplanted for PSC from March 1985 to March 2019. Clinical, biological, and histological data were collected. Risk factors for rPSC were identified using a multivariate Cox-regression model. RESULTS: Five hundred seventy-one patients were included (389 males, 68.1%) with a median age at LT of 42.0 (interquartile range [IQR] 32.0–52.8). Median follow-up after LT was 7.4 years (IQR 3.6–12.6). Overall, rPSC occurred in 25.9% of patients; actuarial risk of developing rPSC at 5, 15, and 25 years was 15.6%, 37.9%, and 52.6%, respectively. The median time to rPSC was 4.9 years (IQR 2.3–8.9). The factors independently associated with rPSC were the presence of IBD (hazard ratio [HR] 1.97, 95% confidence interval [CI] 1.24–3.14), maintenance treatment with corticosteroids (HR 1.76, 95% CI 1.17–2.66), and younger age at LT (HR 1.02 per 1-year increase, 95% CI 1.01–1.03). Type of biliary anastomosis or preventive treatment with ursodeoxycholic acid had no impact on the incidence of rPSC. DISCUSSION: Our results from a large cohort with long-term follow-up strongly confirm that rPSC after LT is frequent. The only modifiable factor associated with rPSC was maintenance treatment with corticosteroids, which could therefore be discontinued in the absence of a specific extrahepatic indication.
15 May 2023 in Clinics and Research in Hepatology and Gastroenterology
Retrospective studies showed a reduction of non-anastomotic strictures (NAS) after cDCD liver transplantation using normothermic regional perfusion (NRP). In the absence of an RCT, a systematic radiological follow-up of recipients is warranted to validate these findings. This single-center retrospective study (01/2015-01/2024) includes all consecutive cDCD liver transplantations performed after A-NRP at a single center. Recipients were included in a prospective radiological follow-up protocol with magnetic resonance cholangiopancreatography (MRCP) to identify NAS, which were defined as strictures of intra- or extra-hepatic bile ducts in the absence of arterial thrombosis. Seventy-one NRP cDCD LTs were included in the study of which 66 (93%) underwent a follow-up MRCP after a median of 180 days. We diagnosed 1 asymptomatic radiological NAS (1.4%) with minor severity (grade E) not requiring treatment. The rate of symptomatic anastomotic biliary complications was 30% (n=21). After a median follow-up of 39 months, we recorded no graft loss related to biliary complications. One- and 5-year graft and recipient survival rates were 94.4% and 85.9%, and 95.8% and 84.6% respectively. This single center 10-year experience with A-NRP for cDCD LT and a prospective MRCP follow-up of recipients shows <2% of NAS with no graft loss related to biliary complications.
Background: De novo malignancies are one of the leading causes of death after liver transplantation (LT), particularly in patients transplanted for alcohol‐related liver disease (ALD). This retrospective study aimed to assess risk factors for malignancies and to evaluate the impact of calcineurin inhibitor (CNI) discontinuation.Methods: From 1990 to 2015, all patients transplanted for ALD were included.Results: A total of 493 patients were included, 77.9% were male and the median age at LT was 54 years. After LT, 278 de novo malignancies were diagnosed in 214 patients (43.4%). The cumulative incidence of de novo malignancies was 16.3% at 5 years, 34.4% at 10 years, and 49.8% at 15 years. In multivariate analysis, the independent risk factors were male gender (HR = 1.6), and active or weaned smoking (HR = 2.0). Discontinuation of CNI was a protective factor (HR = 0.6). Survival after diagnosis of de novo malignancy was 42.7% at 5 years and 27.5% at 10 years.Conclusion: Our results confirm the major incidence of de novo malignancies after LT for ALD, as well as the important role of non‐modifiable risk factors such as smoking and gender. CNI discontinuation is a protective factor, and the only adaptable, and could be proposed in smoker male patients transplanted for ALD.